Antibe Therapeutics Inc. (TSXV: ATE) is one of this year’s TSX Venture 50 companies — the company is engaged in the development of patents and out-licensing of improved compounds of existing drugs. 

Antibe has two primary business segments: Antibe Therapeutics, a pharmaceutical development company, and Citagenix, a marketer and distributor of regenerative medicines serving the dental and orthopedic marketplaces.

The 2019 TSX Venture 50 is a ranking of top performers on the TSX Venture Exchange over the last year. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.

For the full 2019 TSX Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: www.tsx.com/venture50